Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pinaki Biswas

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
International Journal of Antimicrobial Agents|March 30, 2013
All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trialsPaul C McGovern, Michele Wible, Ahmed El-Tahtawy, et al.
Clinical Therapeutics|July 10, 2012
Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysisKamal M F Itani, Pinaki Biswas, Arlene Reisman, et al.
Therapeutics and Clinical Risk Management|September 14, 2016
Safety of long-term use of linezolid: results of an open-label studyJose A Vazquez, Anthony C Arnold, Robert N Swanson, et al.
British Journal of Clinical Pharmacology|November 18, 2009
Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metaboliteBharat D Damle, Howard Uderman, Pinaki Biswas, et al.
Journal of Neuroimmunology|September 26, 2006
Serum IgE reactive against small myelin protein-derived peptides is increased in multiple sclerosis patientsDaniel D Mikol, Charles Ditlow, Danielle Usatin, et al.
Dermatology and Therapy|May 20, 2026
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled AnalysisJonathan I Silverberg, Eric L Simpson, Saleem A Farooqui, et al.
Critical Care (London, England)|October 27, 2011
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasisDaniel H Kett, Andrew F Shorr, Annette C Reboli, et al.
Clinical and Experimental Rheumatology|January 13, 2017
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritisJeffrey R Curtis, Hendrik Schulze-Koops, Liza Takiya, et al.
Dermatology and Therapy|February 4, 2025
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DAREJonathan I Silverberg, Eric L Simpson, Andrew E Pink, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 7, 2019
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid ArthritisChristina Charles-Schoeman, Ryan DeMasi, Hernan Valdez, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
International Journal of Antimicrobial Agents|March 30, 2013
All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trialsPaul C McGovern, Michele Wible, Ahmed El-Tahtawy, et al.
Clinical Therapeutics|July 10, 2012
Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysisKamal M F Itani, Pinaki Biswas, Arlene Reisman, et al.
Therapeutics and Clinical Risk Management|September 14, 2016
Safety of long-term use of linezolid: results of an open-label studyJose A Vazquez, Anthony C Arnold, Robert N Swanson, et al.
British Journal of Clinical Pharmacology|November 18, 2009
Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metaboliteBharat D Damle, Howard Uderman, Pinaki Biswas, et al.
Journal of Neuroimmunology|September 26, 2006
Serum IgE reactive against small myelin protein-derived peptides is increased in multiple sclerosis patientsDaniel D Mikol, Charles Ditlow, Danielle Usatin, et al.
Dermatology and Therapy|May 20, 2026
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled AnalysisJonathan I Silverberg, Eric L Simpson, Saleem A Farooqui, et al.
Critical Care (London, England)|October 27, 2011
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasisDaniel H Kett, Andrew F Shorr, Annette C Reboli, et al.
Clinical and Experimental Rheumatology|January 13, 2017
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritisJeffrey R Curtis, Hendrik Schulze-Koops, Liza Takiya, et al.
Dermatology and Therapy|February 4, 2025
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DAREJonathan I Silverberg, Eric L Simpson, Andrew E Pink, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 7, 2019
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid ArthritisChristina Charles-Schoeman, Ryan DeMasi, Hernan Valdez, et al.
Pageof 6